1. Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer
Darshi et al. Am J Nephrol 2016;44: (DOI: / )
Table 1. A comparison of GC-MS, LC-MS and NMR technologies in metabolomics 

2. Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer
Darshi et al. Am J Nephrol 2016;44: (DOI: / )
Table 2. Summary of metabolites affected in DKD identified by clinical metabolomic analysis

3. Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer
Darshi et al. Am J Nephrol 2016;44: (DOI: / )
Table 3. Summary of metabolomic alterations in animal models of DKD

4. Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer
Darshi et al. Am J Nephrol 2016;44: (DOI: / )
Fig. 1. Overview of urinary metabolite changes in TCA cycle, fatty acid and amino acid metabolism, and affected enzymatic pathways in DKD clinical and preclinical studies. MPC = Mitochondrial pyruvate carrier; PDH = pyruvate dehydrogenase complex; IDH = isocitric dehydrogenase; α-KGDH = alpha ketoglutarate dehydrogenase. Metabolites associated with clinical studies are indicated with red arrows and preclinical studies with blue arrows.